Fluorodeoxyglucose (FDG) PET/CT is the standard for extracranial staging and target volume delineation in patients with newly diagnosed NSCLC. However, the role of invasive staging remains unclear.

If your NSCLC has a higher risk of returning ... These follow-ups will likely include computed tomography (CT) scans and ...

A total of 1,032 CT-based phenotypic characteristics, on intensity, shape, and texture of NSCLC pretherapy image, were identified from 117 stage IV NSCLC patients. This CT-based predictive ...

To diagnose NSCLC, your healthcare team will likely recommend ... Your provider may also recommend a chest computerized ...

CAN-2409 extended median overall survival to 24.5 months in NSCLC patients, surpassing standard docetaxel chemotherapy outcomes. The treatment showed a significant survival benefit in non-squamous ...

The data on SBRT in early-stage NSCLC are mixed. While some studies indicate ... The vast majority in both groups had PET-CT staging, reflecting modern imaging-based workups.

Panelists discuss how the five-year prognosis for advanced non-small cell lung cancer (NSCLC) has improved with PD-1 inhibitors, showing promising overall survival (OS) and progression-free survival ...

RET fusion-positive NSCLC patients benefit from targeted therapies like Retevmo and Gavreto, recommended by NCCN guidelines for first-line treatment. Gavreto demonstrated a 57% overall response rate ...

BlossomHill Therapeutics, Inc., a privately-held, clinical-stage biotechnology company focused on the design and development of small molecule medicines for treating cancer and autoimmune diseases, ...

SAN ANTONIO, March 26, 2025--bioAffinity Technologies' CyPath Lung test uncovered a hidden second primary lung cancer in a patient who had been treated for lung cancer earlier.